Literature DB >> 26362228

Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study.

R O C Araujo1, M Valadão2, D Borges2, E Linhares2, J P de Jesus2, C G Ferreira3, A P Victorino3, F M Vieira4, R Albagli2.   

Abstract

INTRODUCTION: Surgery is the standard treatment of rectal cancer after neoadjuvant therapy. Some authors advocate a nonoperative management (NOM) after complete clinical response (cCR) following chemoradiotherapy (CRT). We compare our results with NOM to standard resection in a retrospective analysis.
METHODS: Rectal adenocarcinomas submitted to NOM after CRT between September 2002 and December 2013 were compared to surgical patients that had pathological complete response (pCR) during the same period. Endpoints were Overall Survival (OS), Disease Free Survival (DFS), Local Relapse (LR) and Distant Relapse (DR).
RESULTS: Forty-two NOM patients compared to 69 pCR patients operated after a median interval of 35 weeks after CRT. NOM tumors were distal (83.3% vs 59.4%, p = 0.011), less obstructive (26.2% vs 54.4%, p = 0.005) and had a lower digital rectal score (p = 0.024). Twelve (28.0%) recurrences in NOM group and eight (11.5%) in the surgical group occurred after a follow-up of 47.7 and 46.7 months respectively. Isolated LR occurred in five (11%) NOM patients and one (1.4%) in the surgical group. Four (80%) LR were surgically salvaged in NOM group. No difference in OS was found (71.6% vs 89.9%, p = 0.316) but there was a higher DFS favoring surgical group (60.9% vs 82.8%, p = 0.011). Distal tumors had worse OS compared to proximal tumors in surgical group (5-year OS of 85.5% vs 96.2%, p = 0.038).
CONCLUSION: The NOM achieved OS comparable to surgical treatment and spared patients from surgical morbidity but it resulted in more recurrences. This approach cannot be advocated routinely and controlled trials are warranted.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Complete clinical response; Neoadjuvant therapy; Nonoperative treatment; Rectal cancer; Rectal resection

Mesh:

Substances:

Year:  2015        PMID: 26362228     DOI: 10.1016/j.ejso.2015.08.156

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  24 in total

1.  Preoperative chemoradiotherapy affects postoperative outcomes and functional results in patients treated with transanal endoscopic microsurgery for rectal neoplasms.

Authors:  G Rizzo; D P Pafundi; F Sionne; L D'Agostino; G Pietricola; M A Gambacorta; V Valentini; C Coco
Journal:  Tech Coloproctol       Date:  2021-01-18       Impact factor: 3.781

Review 2.  Non-operative management of rectal cancer: understanding tumor biology.

Authors:  Iris H Wei; Julio Garcia-Aguilar
Journal:  Minerva Chir       Date:  2018-05-24       Impact factor: 1.000

Review 3.  Management of the Complete Clinical Response.

Authors:  Angelita Habr-Gama; Guilherme Pagin São Julião; Bruna Borba Vailati; Ivana Castro; Debora Raffaele
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

4.  Systematic review and meta-analysis on outcomes of salvage therapy in patients with tumour recurrence during 'watch and wait' in rectal cancer.

Authors:  J On; J Shim; E H Aly
Journal:  Ann R Coll Surg Engl       Date:  2019-03-11       Impact factor: 1.891

Review 5.  Should the rectal defect be closed following transanal local excision of rectal tumors? A systematic review and meta-analysis.

Authors:  B Menahem; A Alves; R Morello; J Lubrano
Journal:  Tech Coloproctol       Date:  2017-11-13       Impact factor: 3.781

6.  Is It Possible a Conservative Approach After Radiochemotherapy in Locally Advanced Rectal Cancer (LARC)? A Systematic Review of the Literature and Meta-analysis.

Authors:  Francesco Fiorica; Marco Trovò; Gabriele Anania; Daniele Marcello; Fabrizio Di Benedetto; Marina Marzola; Fabrizio D'Acapito; Guglielmo Nasti; Massimiliano Berretta
Journal:  J Gastrointest Cancer       Date:  2019-03

7.  Wait and see approach for rectal cancer with a clinically complete response after neoadjuvant concurrent chemoradiotherapy.

Authors:  Hyun Jung Kim; Jin Ho Song; Hyeong Sik Ahn; Bong-Hoi Choi; Hojin Jeong; Hoon Sik Choi; Yun Hee Lee; Ki Mun Kang; Bae Kwon Jeong
Journal:  Int J Colorectal Dis       Date:  2016-11-24       Impact factor: 2.571

Review 8.  Organ Preservation in Rectal Cancer.

Authors:  Jonathan B Yuval; Hannah M Thompson; Julio Garcia-Aguilar
Journal:  J Gastrointest Surg       Date:  2020-04-20       Impact factor: 3.452

9.  Nonoperative Management or 'Watch and Wait' for Rectal Cancer with Complete Clinical Response After Neoadjuvant Chemoradiotherapy: A Critical Appraisal.

Authors:  Tarik Sammour; Brandee A Price; Kate J Krause; George J Chang
Journal:  Ann Surg Oncol       Date:  2017-03-21       Impact factor: 5.344

10.  Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy.

Authors:  Filippo Landi; Eloy Espín; Victor Rodrigues; Francesc Vallribera; Aleix Martinez; Cecile Charpy; Francesco Brunetti; Daniel Azoulay; Nicola de'Angelis
Journal:  Int J Colorectal Dis       Date:  2016-10-19       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.